Premium
Transfusion‐dependent thalassaemic patients with renal F anconi syndrome due to deferasirox use
Author(s) -
Chuang GwoTsann,
Tsai IJung,
Tsau YongKwei,
Lu MengYao
Publication year - 2015
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/nep.12523
Subject(s) - deferasirox , medicine , incidence (geometry) , creatinine , pediatrics , cohort , urinalysis , adverse effect , thalassemia , urine , physics , optics
Aim Deferasirox is a new oral iron chelating agent with several cases reporting renal adverse events in recent years. Our aim was to identify the incidence of deferasirox‐related F anconi syndrome ( FS ) and its risk factors. Methods All transfusion‐dependent thalassaemic patients who received deferasirox at the outpatient department of the National T aiwan University Hospital ( NTUH ) from J anuary 2006 to F ebruary 2014 were evaluated. Results This cohort study included 57 patients, and mean age of deferasirox initiation was 18.2 ± 7.7 years. After 6.9 ± 1.8 years of follow‐up, 5 in 57 (8.8%) thalassaemic patients had FS . Age of starting deferasirox negatively correlated with incidence of FS (correlation coefficient −0.892, P = 0.008). Other factors were not significantly associated with FS . Serum creatinine level at the start of deferasirox compared to at the end of study or onset of FS did not show significant change ( P = 0.277). All the deferasirox‐related FS manifested with proximal renal tubular acidosis and hypophosphataemia, which needed specific treatment or withdrawal of deferasirox use. Conclusions We recommend that children, especially of young age, who regularly use deferasirox should undergo routine urinalysis and blood testing for early detection of FS .